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Abstract
Background: Prior genomewide scans of schizophrenia support evidence of linkage to regions of chromosome 20.
However, association analyses have yet to provide support for any etiologically relevant variants.
Methods: We analyzed 2988 LD-tagging single nucleotide polymorphisms (SNPs) in 327 genes on chromosome 20, to test
for association with schizophrenia in 270 Irish high-density families (ISHDSF, N=270 families, 1408 subjects). These SNPs
were genotyped using an Illumina iSelect genotyping array which employs the Infinium assay. Given a previous report of
novel linkage with chromosome 20p using latent classes of psychotic illness in this sample, association analysis was also
conducted for each of five factor-derived scores based on the Operational Criteria Checklist for Psychotic Illness (delusions,
hallucinations, mania, depression, and negative symptoms). Tests of association were conducted using the PDTPHASE and
QPDTPHASE packages of UNPHASED. Empirical estimates of gene-wise significance were obtained by adaptive permutation
of a) the smallest observed P-value and b) the threshold-truncated product of P-values for each locus.
Results: While no single variant was significant after LD-corrected Bonferroni-correction, our gene-dropping analyses
identified loci which exceeded empirical significance criteria for both gene-based tests. Namely, R3HDML and C20orf39 are
significantly associated with depressive symptoms of schizophrenia (Pemp,2610
25) based on the minimum P-value and
truncated-product methods, respectively.
Conclusions: Using a gene-based approach to family-based association, R3HDML and C20orf39 were found to be
significantly associated with clinical dimensions of schizophrenia. These findings demonstrate the efficacy of gene-based
analysis and support previous evidence that chromosome 20 may harbor schizophrenia susceptibility or modifier loci.
Citation: Bigdeli TB, Maher BS, Zhao Z, van den Oord EJCG, Thiselton DL, et al. (2011) Comprehensive Gene-Based Association Study of a Chromosome 20 Linked
Region Implicates Novel Risk Loci for Depressive Symptoms in Psychotic Illness. PLoS ONE 6(12): e21440. doi:10.1371/journal.pone.0021440
Editor: Xiang Yang Zhang, Baylor College of Medicine, United States of America
Received February 3, 2011; Accepted May 27, 2011; Published December 29, 2011
Copyright:  2011 Bigdeli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: TBB was supported by U.S. National Institutes of Health grant 5R25DA026119-03. BSM, BPR and KSK were supported by U.S. National Institute of Mental
Health grant MH083094. BPR and KSK were supported by grants MH041953 and MH068881. ZZ was supported by U.S. National Institutes of Health grant
AA017437 and a NARSAD Maltz Investigator Award. AHF was supported by a grant from the Department of Veterans Affairs Merit Review Program. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ayman.fanous@va.gov
Introduction
With a lifetime prevalence of 1 percent and an estimated annual
cost of $62.7 billion in the United States [1], schizophrenia (Scz) is
a debilitating neuropsychiatric disorder which poses a significant
burden to public health. Whether schizophrenia represents a
single or multiple disease processes is a source of persistent
controversy, as patients vary considerably in onset, course and
outcome of disease, and the particular combination of symptoms
endorsed [2,3]. Models comprising continuous traits—often
extracted in factor analysis of symptom profiles—have been
adduced, typically distinguishing positive, negative, disorganiza-
tion, and affective symptoms [4]. One explanation for this
variability lies in the existence of more than one putative
etiopathogenic mechanism, each imparting susceptibility to a
more or less distinct disease subtype or influencing the character of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e21440illness dimensionally. Detection and subsequent replication of
several putative risk variants, facilitated by genome-wide associ-
ation studies (GWAS) [5–10], has seen renewed interest in this
question among geneticists and diagnosticians alike [11–13].
Consistent with the observed variability in clinical presentation
is the hypothesis that schizophrenia is likely genetically heteroge-
neous [6,8]. Linkage and candidate gene association studies have
implicated a number of genes and genomic regions, with varying
degrees of subsequent independent replication. Allelic heteroge-
neity has been demonstrated in meta-analyses of candidate genes
such as DTNBP1 [14,15]. If the observed clinical heterogeneity of
schizophrenia is in fact due to genetic heterogeneity, the use of
more clinically homogenous phenotypes may increase the signal-
to-noise ratio in gene-finding studies. A previous report by our
group described detection of novel linkage to 20p using latent
classes of psychotic illness [16]. Linkage analysis of Mania,
Schizomania, Deficit Syndrome and Core Schizophrenia latent
classes yielded several suggestively significant loci, in regions of
chromosome 20 which had previously yielded very little evidence
of linkage in our sample. Furthermore, the presence of
susceptibility genes in chromosome 20 has been suggested by
several previous linkage studies as well [17–23]. In addition to
genes which increase susceptibility to more or less distinct clinical
subtypes of illness, other genes may influence clinical features of
disease in a dimensional fashion, without altering liability to the
illness itself. These have previously been described as modifier loci
[2]. Modifier loci may not be resolvable using traditional
dichotomous phenotypes (simply ‘‘affected’’ or ‘‘unaffected’’), but
rather, by quantitative symptomatic measures. Several examples
have been reported [24–30].
Recent GWAS of schizophrenia support a polygenic model in
which potentially thousands of common variants individually
impart small effects. Given the unprecedented multiple-compar-
ison burden incurred in a genome-wide approach, hypothesis-
based strategies remain viable alternatives for the study of complex
disease. A gene-based approach is particularly convenient. In an
analysis of bipolar and schizophrenia datasets, Moskvina and
colleagues [31] observed significantly more SNPs within genes
showing evidence for association than expected, with intergenic
SNPs showing no such trend.
We describe a comprehensive, gene-based association survey of
327 genes in regions linked to chromosome 20 in our previous
studies. In addition to testing for association with traditional
diagnostic definitions of schizophrenia, we also sought to assess
whether chromosome 20 harbors modifier loci. Association
analysis was therefore also performed for five factor-derived
scores, representing hallucinations, delusions, depressive symp-
toms, manic symptoms, and negative symptoms, in schizophrenia
cases only. In addition to single-marker tests of allelic association,
we employ two gene-based test-statistics, the minimum observed
P-value per gene and the truncated product of P-values, to
evaluate the efficacy of a gene-based approach as applied to a
large, family-based study.
Results
Gene-wide Association Analyses
Following quality-control protocols, 2,988 single nucleotide
polymorphisms in 327 genes were tested for association with a
diagnosis of schizophrenia (Figure 1). Estimates of empiric
significance (Pemp) were obtained via an adaptive permutation
procedure employing the smallest observed P-value, as well as the
truncated product of P-values (atrunc#0.01) per gene. The number
of genes carried forward in successive stages of this procedure, in
both approaches, can be found in Table 1. Using the minimum
gene-wide P-value approach, no genes were observed to be
significantly associated with narrow (N=1574), intermediate
(N=1749), or broad (N=1808) diagnoses of schizophrenia. Next,
we sought to identify those SNPs associated with clinical
dimensions of schizophrenia in a subset of cases (N=721) for
which the OPCRIT was available. A previous report by Fanous
and colleagues [16] supports linkage of latent classes derived from
the OPCRIT to chromosome 20 in this sample. No genes were
found to be significantly associated with the negative, manic,
hallucinations or delusions factors. In the analysis of the clinical
dimensions, R3HDML demonstrated significant evidence of
association (Pemp,2610
25) with the depressive factor using the
minimum P-value approach. Using the truncated product of P-
values, C20orf39 was also found to be significantly associated with
the depressive factor (Pemp,261025). It is important to note that,
for both C20orf39 and R3HDML, we observed fewer than ten
simulated results more significant than the observed test-statistic
after 100,000 permutations. Hence, our estimates of empirical
significance may be conservative. However, extending our
analyses to 1 M permutations was not carried out as it was too
computationally demanding.
Because validation of a truncated product approach in extended
pedigrees relies on the permutation procedure faithfully conserv-
ing patterns of LD within each replicate dataset, we obtained a
quantitative measure of how well haplotype-block structure was
maintained for C20orf39 across actual and simulated datasets. In
calculating an LD-corrected significance threshold, SNPSpD
estimates the effective number of independent tests present in a
set of markers. Using SNPSpD, 1,000 replicate datasets for
C20orf39 were assessed for number of independent tests. When
compared to the estimate based on the actual pattern of LD in
C20orf39 (i.e., 26 independent tests), the distribution of these
simulation-derived estimates demonstrates that the LD structure
within each replicate does not differ significantly from the
observed data (P<0.409; 95% CI: [26,28]). This increases
confidence in the truncated product finding for C20orf39.
However, this may not hold for every gene and may be sensitive
to specific patterns of linkage disequilibrium.
Single Marker Association Analysis
Taking each SNP to represent an independent hypothesis but
correcting for LD using SNPsPD, we found that no single marker
met experiment-wide criteria for association (aSNPsPD,
3.1861025) with either the three categorical diagnostic definitions
used or our OPCRIT-derived factor scores (Tables 2, 3). The
strongest evidence of association with a diagnosis of schizophrenia
was in PLCB1 (20p12.3) (rs6108205, P<1.00610
23, intermediate
Scz diagnosis). For the depressive factor, we observed the strongest
associations experiment-wide at 20q13.12 (rs3761184,
P<3.31610
25)i nR3HDML This was very close to the LD-
corrected significance threshold calculated using SNPSpD
(P=3.18610
25). Furthermore, rs11700002, in C20orf39 at
20p11.21 attained P<1.01610
24.
Discussion
We have conducted a comprehensive gene-based association
study of 327 genes on chromosome 20 in an Irish sample of 270
high-density schizophrenia families. This study sought to identify
common variants conferring susceptibility to schizophrenia,
following up reported linkage in this sample to clinical subtypes
of psychotic illness [16], as well as previous studies reporting
linkage to chromosome 20. Because those clinical subtypes were
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e21440derived from quantitative symptom dimensions, we also tested for
association with these same dimensions. Although traditional
single-marker tests failed to identify any SNPs meeting experi-
ment-wide criteria for significance, application of gene-wide
association metrics revealed two previously unimplicated loci,
R3HDML and C20orf39, associated with depressive symptoms.
Our findings support the power of gene-based association
approaches. They also lend further support to previous evidence
suggesting that genetic differences may underlie clinical heteroge-
neity in schizophrenia [2,3].
One of the aims of this study was to identify genomic loci
predisposing to a particular form of illness or which modifies
clinical presentation amongst affected individuals. Such genes have
been described previously as ‘‘modifier’’ or ‘‘susceptibility-
modifier’’ loci and are reviewed elsewhere [2]. Of the two loci
showing the strongest associations, namely R3HDML and
C20orf39, neither appears to affect the risk of the illness itself.
That is, no single variant in either gene met even nominal
significance criteria (P,0.05) for association with narrow,
intermediate, or broad diagnoses of schizophrenia. These two
genes would therefore fulfill our definition of modifier genes [2].
However, the strength of evidence we observed for R3HDML is
greater than that observed for C20orf39. R3HDML was identified
by application of the minimum P-value approach. Among affected
individuals, those carrying the minor allele (G) of the correspond-
ing SNP, rs3761184, had higher mean depression scores. On the
other hand, for C20orf39, empirical significance was attained using
the truncated product of P-values. This makes it more difficult to
identify a specific risk genotype. This is because the truncated
product method only considers all variation within a gene jointly.
In Figure 2, it is apparent that those markers contributing to the
truncated product for C20orf39 comprise a block of LD distinct
Figure 1. Physical distribution of single-marker associations on chromosome 20, for both categorical diagnoses and clinical
dimensions of Scz. Associations are displayed as log-transformed P-values (2log10P) at genomic positions in megabases (Mb). Where appropriate, a
dotted line indicates the Bonferroni-corrected significance threshold, accounting for number of SNPs assayed experiment-wide. Similarly, a dashed
line indicates the LD-corrected significance threshold, as estimated by SNPSpD.
doi:10.1371/journal.pone.0021440.g001
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association of the minor allele with higher depression scores.
Whereas individually, none of the single-marker associations were
significant after our permutation procedure, the degree of
correlation between the SNPs may have been sufficient to produce
an empirically significant association for C20orf39 as a whole. In
order to rule out a spurious gene-wise association due to higher
LD, we analyzed a set of permutations using SNPSpD, then
compared the distribution of estimated number of independent
tests (SNPs) to that obtained for the actual data. If our gene-
dropping simulations were found to consistently underestimate the
extent of LD between adjacent markers—indicated by a larger
number of independent tests—we would expect an inflation of the
empiric test-statistic. Alternatively, if the observed LD within
simulated datasets tended to overestimate pairwise LD, the
corresponding distribution of truncated products would underes-
timate the empiric test-statistic. For C20orf39, the observed
SNPSpD estimate of , 26 tests was not found to differ significantly
from the null distribution of simulated datasets, suggesting that our
gene-dropping procedure was faithfully conserving LD-structure
across our simulations. As discussed, increased gene-size, especially
in the presence of higher LD between markers, might also
contribute to over-estimation of the test statistic.
To our knowledge, neither R3HDML nor C20orf39 has been
functionally characterized to date. Both are predicted genes
identified on the basis of domain homology. The R3HDML locus
encodes a putative serine protease inhibitor belonging to the
CRISP family of cysteine-rich secretory proteins, and contains
evolutionarily conserved exonic and intronic regions bearing
greater than 90% similarity to Rhesus macaque [32]. Interspersed
within the conserved intronic sequences are numerous stretches of
simple tandem repeats (e.g. CGn). Our SNP of interest in
Table 1. Number of genes requiring additional simulations at each stage of adaptive permutation.
Trait
Min P
(100)
Min P
(1 K)
Min P
(10 K)
Min P
(100 K)
Trunc Prod P
(100)
Trunc Prod P
(1 K)
Trunc Prod P
(10 K)
Trunc Prod P
(100 K)
Diagnostic Category Narrow 19 5009 5 0 0
Diagnostic Category I n t1 2 4006 4 2 0
Diagnostic Category B r o a d 1 4 3005 3 0 0
Symptom Factor d e l1 5 4008 4 0 0
Symptom Factor dep 10 6 1 1
{ 9421
{
Symptom Factor h a l6 2004 1 0 0
Symptom Factor m a n i c 5 2001 4 6 0 0
Symptom Factor n e g 2 0 4001 4 7 0 0
For each diagnosis and symptom factor, the number of loci requiring additional permutations after each stage of our adaptive procedure, given for both the Min P and
truncated-product methods. For an observed test-statistic to be considered significant at a particular stage of permutation, there may be no greater than 10 simulated
null statistics which are more extreme than the observed. For each gene-based test, the number of permutations performed at each stage is displayed parenthetically
(100, 1,000, 10,000, and 100,000). Dim codes ‘‘del’’, ‘‘dep’’, ‘‘hal’’, ‘‘manic’’, ‘‘neg’’ are delusions, depressive symptoms, hallucinations, mania, and negative symptoms,
respectively, and described elsewhere in full.
{Min P finding for R3HDML.
{truncated-product finding for C20orf39.
doi:10.1371/journal.pone.0021440.t001
Table 2. Top ten Pedigree Disequilibrium Test results for categorical diagnoses of Schizophrenia.
Chr/Mb Gene dbSNP Nuc.(Minor) Assoc. Frqassoc Trios(Tr/NTr)
DSPs(Aff/
Unaff) Z-score x
2 P Dx
20/0.92 RSPO4 rs6056462 A/G(G) A 0.842 94/90 868/855 3.171 10.05 1.52610
23 Int
20/0.92 RSPO4 rs6056462 A/G(G) A 0.843 97/93 911/897 3.170 10.05 1.53610
23 Broad
20/8.79 PLCB1 rs6108205 C/T(C) C 0.491 67/65 536/467 3.289 10.82 1.00610
23 Int
20/8.79 PLCB1 rs6108205 C/T(C) C 0.490 58/56 444/391 3.182 10.13 1.46610
23 Narrow
20/10.60 JAG1 rs6133987 C/T(T) C 0.778 85/78 678/610 3.193 10.19 1.41610
23 Narrow
20/40.41 PTPRT rs6072690 A/G(A) A 0.442 67/59 586/502 3.224 10.40 1.26610
23 Broad
20/40.51 PTPRT rs6130134 C/T(T) C 0.792 94/93 880/826 3.152 9.940 1.62610
23 Int
20/42.07 TOX2 rs6103560 C/T(T) C 0.705 111/95 855/822 3.200 10.24 1.37610
23 Broad
20/44.19 CD40 rs3765457 A/G(G) G 0.175 24/24 235/170 3.154 9.950 1.33610
23 Broad
20/44.19 CD40 rs3765457 A/G(G) G 0.176 23/23 223/160 3.210 10.30 1.61610
23 Int
For each gene, Chr/Mb denotes chromosome and genomic position (Megabases), dbSNP is the rs-identifier for the assayed SNP, and Nuc is the nucleotide substitution at
a SNP. Frqassoc and Z-scores are with respect to the associated allele. Allelic transmissions from parent to affected child is given by Trios, where Tr and NTr represent
number of transmissions and non-transmissions. Allele-sharing between phenotypically-discordant sib-pairs is given by DSPs, with Aff/Unaff denoting the number of
associated alleles in affected and unaffected siblings, respectively. Dx codes ‘‘Core’’, ‘‘Int’’, and ‘‘Broad’’ are Core, Intermediate, and Broad diagnoses of schizophrenia,
respectively, and are described elsewhere in full.
doi:10.1371/journal.pone.0021440.t002
Novel Chr20 Associations with Depression in Scz
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e21440R3HDML, rs3761184, falls just upstream (,50 bp) of the second
exon and 150 bp downstream of one such repeat-rich region.
Roles in fertilization, spermatogenesis, and pathogen response
have all been proposed for CRISP proteins, but these mechanisms
are not immediately supportive of R3HDML as a schizophrenia
candidate gene. However, recent implication of a number of HLA
genes in large-scale GWAS suggest that genes involved in
immune-related mechanisms, such as pathogen response, could
be reasonable Scz candidates [8]. The presence of specific
sequence features in the vicinity of the associated SNP may
warrant more thorough bioinformatic inquiry. Additionally,
R3HDML lies approximately 57 kb downstream of the GDAP1L1
locus, which appears to encode a gluthionine S-transferase (GST).
Cell-culture studies have demonstrated a relationship between
gluthionine deficiency and oxidative stress, mechanisms frequently
purported to contribute to schizophrenia pathophysiology [33,34].
However, GDAP1L1 was not significantly associated.
Our empirically significant finding for C20orf39 presents
additional challenges for interpretation, given its provisional status
as an ‘‘open reading frame’’. Provisionally known as TMEM90B,
this locus encodes a predicted transmembrane protein. Of 33
SNPs assayed within C20orf39, the nine included in the truncated
product bounded a region of LD corresponding to the coding
region of C20orf39. The upstream, untranslated region of
C20orf39, which itself corresponds to a distinct set of ESTs,
yielded no SNPs meeting local significance criteria. Whether the
markers driving this association simply lie in joint linkage
disequilibrium with nearby causal variation, or actually demarcate
an etiologically relevant genomic region, is unknown.
Depressive symptoms, especially suicidal ideation, comprise a
considerable portion of morbidity and mortality in schizophrenia
[35]. Therefore, follow up of these two genes could be important
in the search for clues to more successful identification and
treatment of this clinical dimension.
As demonstrated by Moskvina et al., polymorphisms mapping to
functional elements are more likely to be associated with complex
disease than intergenic variation [31]. Despite ongoing annotation
and characterization of functional elements, however, our
knowledge of genomic variation, functional or otherwise, remains
incomplete. This is exemplified by C20orf39 and R3HDML, which
are novel and unannotated.
A major benefit of gene-based approaches is that they are robust
to allelic and haplotypic heterogeneity across samples. This makes
them particularly suited for use in replication and meta-analysis.
In traditional replication of single-marker associations, the
associated SNP in the discovery sample is usually assayed in all
subsequent replication samples. This could inflate Type-II error in
the presence of population differences in haplotype structure and
allele frequencies [36]. Complex patterns of associations, whether
spurious or due to genetic heterogeneity, have been more the rule
rather than the exception in candidate gene studies of complex
disease, as demonstrated by studies of DTNBP1 [14,15]. For
discovery-based approaches, adoption of a gene-based strategy
may be of even more immediate benefit, specifically by providing a
straightforward means of multiple-test correction. Furthermore,
traditional methods to correct for multiple-testing, such as
Bonferroni correction or the less overtly conservative SNPSpD
method, may be less robust in detecting small genetic effects.
However, in spite of the advantages of gene-based association
studies intergenic causative variants or variants in unrecognized
genes might have been missed in this study.
Given the poor spatial resolution of linkage and intrinsic
differences between these methodologies, we are currently unable
to fully relate our association findings with the results of our
previously published linkage study of latent classes. However, it is
notable that R3HDML is located in a region which was linked to
the ‘‘deficit syndrome’’ latent class, for which members were
substantially more likely to fall below the median for depressive
symptoms. Despite failing to demonstrate any evidence of
association with a diagnosis of schizophrenia, R3HDML may be
associated with a disease subtype characterized by low levels of
depression. Because subtyping precludes use of our full sample for
association analysis, statistical power is insufficient to test this
hypothesis. Other methods aiming to identify more clinically
homogenous subgroups have been applied to linkage analysis of
schizophrenia. In a study of 168 affected sibling pairs, Hamshere
and colleagues [37] demonstrated that inclusion of major
depression as a covariate yielded suggestive evidence of linkage
at 20q11.21, while schizophrenia as a whole did not. Taken
together, these studies are compelling in their support of 20q11
harboring genes relevant to the affective component of schizo-
phrenia. Emerging evidence supports a role for genetic variants
Table 3. Top ten Quantitative Pedigree Disequilibrium Test results for clinical dimensions of Schizophrenia.
Chr/Mb Gene dbSNP Nuc.(Minor) Assoc. Frqassoc
Gametes
(maj/min) Z-score x
2 PD i m
20/0.83 ANGPT4 rs976166 C/G(C) C 0.308 1285/571 3.333 11.11 8.59610
24 neg
20/9.70 PAK7 rs2327225 A/C(C) A 0.718 1333/523 3.426 11.74 6.13610
24 manic
20/10.59 JAG1 rs6133986 A/G(A) A 0.089 1691/165 3.523 12.41 4.27610
24 manic
20/16.66 SNRPB2 rs6111262 C/T(T) C 0.720 1337/519 3.281 10.76 1.04610
23 del
20/17.58 RRBP1 rs3790310 A/T(A) T 0.809 1502/354 3.451 11.91 5.58610
24 neg
20/24.54 C20orf39 rs11700002 A/G(A) A 0.187 1509/347 3.930 15.44 8.50610
25 dep
20/24.56 C20orf39 rs4815292 G/T(G) G 0.353 1201/655 3.362 11.30 7.73610
24 dep
20/24.58 C20orf39 rs11696125 G/T(T) T 0.230 1430/426 3.392 11.50 6.94610
24 dep
20/24.58 C20orf39 rs11087473 A/G(A) A 0.230 1430/426 3.392 11.50 6.94610
24 dep
20/42.40 R3HDML rs3761184 A/G(G) G 0.169 1543/313 4.120 16.98 3.78610
25 dep
For each gene, Chr/Mb denotes chromosome and genomic position (Megabases), dbSNP is the rs-identifier for the assayed SNP, and Nuc is the nucleotide substitution at
a SNP. Gametes represents the number of major and minor alleles (maj/min) transmitted from parent to affected child or unshared between phenotypically-discordant
sib-pairs. Frqassoc and Z-scores are with respect to the allele corresponding to a higher trait mean. Dim codes ‘‘del’’, ‘‘dep’’, ‘‘hal’’, ‘‘manic’’, ‘‘neg’’ are delusions, depressive
symptoms, hallucinations, mania, and negative symptoms, respectively, and described elsewhere in full.
doi:10.1371/journal.pone.0021440.t003
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Furthermore, genome scans of both disorders have consistently
implicated regions of chromosome 20 [39–44]. A recent study of
383 bipolar or schizoaffective relative pairs found suggestive
linkage at 20q13.31 when conditioning on the presence of mood-
incongruent psychosis, furthering the argument that chromosome
20 loci may have relevance to conditions containing admixtures of
mood and psychotic symptoms [45].
The findings presented here provide additional support to
published findings suggesting that schizophrenia modifier loci may
exist on chromosome 20 and, more generally, that genetic
differences underlie clinical heterogeneity in schizophrenia [46].
We await replication of the observed associations between these loci
and either categorically defined illness or more or less distinct
subtypes or clinical dimensions. There are two main limitations
relevant to this study. First, the truncated product of P-values is
particularly sensitive to patterns of LD (unpublished results), since
markers could be significant only due to their LD with other
significant markers. Applied to family-based analysis of extended
pedigrees,the validityofgene-based testing relies on thepermutation
method realistically maintaining LD across simulated datasets. As
discussed, for C20orf39, the LD structure for a random sample of
simulated datasets did not differ significantly from the actual data
(P.0.05).Second, ouranalysisofmultiple symptomdimensionsmay
increase the Type-I error rate due to multiple testing. However, as
we have previously shown, these dimensions are correlated [47],
making Bonferroni correction overly conservative. It remains
unclear whether the failure of traditional approaches to detect
experiment-wide significant loci reflects the spurious nature of these
findings or simply the limited power of this sample. Ultimately, the
genotype-phenotype correlations reported herein require confirma-
tion in independent samples for which comparable symptom
measures are available. We are unaware of other family-based
schizophrenia samples in which OPCRIT data are readily available.
However, this is likely to be attempted incase-control samples by the
Psychiatric GWAS Consortium Cross-Disorders Group [13].
Methods
Ethics Statement
This research was approved by the Institutional Review Boards
of Virginia Commonwealth University School of Medicine and the
Figure 2. Association of C20orf39 SNPs with depressive symptoms of Scz. Magnitudes and directions of associations are displayed in the
upper panel, with upwards-oriented triangles indicating a positive correlation with symptom factor score. A dashed line is provided at the inclusion
threshold for the truncated product of P-values. Connecting lines relate the physical positions of associations to SNP labels in the corresponding LD-
map (r
2). Plot generated using snp.plotter for R [66].
doi:10.1371/journal.pone.0021440.g002
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participate in research, as this was the norm in Ireland at the time
these data were collected.
Sample
Fieldwork for the Irish Study of High Density Schizophrenia
Families (ISHDSF) was conducted between April 1987 and
November 1992, with probands ascertained from public psychi-
atric hospitals in Ireland and Northern Ireland [48]. Selection
criteria were two or more first-degree relatives meeting DSM-III-
R criteria for schizophrenia or poor-outcome schizoaffective
disorder (PO-SAD). Diagnoses were based on the Structured
Interview for DSM-III-R Diagnosis (SCID) [49]. Independent
review of all pertinent diagnostic information was made blind to
pedigree assignment and marker genotypes by KSK and DW,
with each diagnostician making up to three best-estimate DSM-
III-R diagnoses. The Operational Criteria Checklist for Psychotic
Illness (OPCRIT) [50] was completed by KSK for all subjects with
probable lifetime histories of hallucinations or delusions (N=755;
N=722 genotyped). Our diagnostic schema contains 4 concentric
definitions of affection: narrow (D2) (schizophrenia, PO-SAD, and
simple schizophrenia) (N=577), intermediate (D5) which adds to
D2 schizotypal personality disorder, schizophreniform and
delusional disorders, atypical psychosis and good-outcome SAD
(N=700), broad (D8) (all disorders which significantly aggregated
in relatives of probands) (N=754) and very broad (D9), including
any psychiatric illness (N=961). Exploratory and confirmatory
factor analysis of the OPCRIT was conducted previously by
Fanous et al. [47]. This yielded a five-factor solution, comprising
depressive, manic, and negative symptoms, delusions and
hallucinations. Factor-derived scores were obtained by summing
the scores of all items belonging to each factor.
Bioninformatics and SNP-selection
Using WebGestalt [51], a total of 378 genes were initially
identified as mapping to the region of chromosome 20
corresponding to the peak NPL and to the positions corresponding
to a NPL of at least 1 on either side, based on the Illumina version
4.0 linkage SNP map used for genotyping in a multicenter linkage
study funded by R01-MH068881 [52]. While there was very little
evidence of linkage in our published microsatellite-based scan [53],
we did observe modest evidence using the map in the Holmans et
al. study [52], which included our study sample (results available
on request). We included predicted genes and open reading frames
(ORFs) from the p-terminal to 45.85 Mb (20q13.13). Physical map
positions for 362 genes were obtained from the UCSC Genome
Browser (hg17/NCBI Build 35) [54]. Tagging SNPs were selected
for each identified genomic region (excluding upstream and
downstream regions of genes) using Tagger (r
2$0.8, minor allele
frequency (MAF)$0.1) [55], as applied to the HapMap CEPH
dataset [56]. Of these, 31 genes were excluded on the basis of
tagging SNPs being unavailable. After removing multiple
occurrences of markers resulting from overlap of adjacent genomic
regions, 3,386 SNPs in 331 genes were selected for inclusion
(Table S1).
Genotyping
Genotyping was conducted by Illumina, Inc. using a custom
iSelect array, which employs the Infinium assay. In total, DNA for
1,128 individuals was submitted for genotyping of 3,386 SNPs. As
SNP markers from several ongoing experiments were included on
the same array, per-individual summary statistics reflect genotyp-
ing across a total of 7,500 SNPs. Average genotyping completion
rate across all SNPs was 99.97%. Of 1,128 samples, 21 failed to
yield usable genotypes. Genotypes were examined for apparent
Mendelian incompatibilities using PEDCHECK v 1.1 [57] and
removed for entire families where appropriate.
Association Analysis
We performed association analysis for categorical diagnoses of
schizophrenia using PDTPHASE (UNPHASED v. 2.404), an
implementation of the pedigree disequilibrium test (PDT) with
extensions to deal with uncertain haplotypes and missing data
[58,59]. The PDT is an extension of the transmission disequi-
librium test (TDT) to examine general pedigree structures and is
similarly a test of association in the presence of linkage.
Association with quantitative measures of disease was assessed
using QPDTPHASE (UNPHASED v. 2.404), an implementation
of the quantitative trait PDT with extensions to deal with
uncertain haplotypes and missing data [59,60]. An LD-corrected
significance threshold was obtained using the SNPSpD package
for R [61,62]. For 2,988 SNPs, SNPSpD calculated an estimated
1,569 independent tests, with a corresponding significance
threshold of aSNPSpD<3.18610
25, maintaining the type I error
rate at 5%.
Gene-wide Tests of Empirical Significance
Estimates of empirical significance for association results were
obtained by adaptive permutation of gene-dropping simulations
created with MERLIN [63]. Simulated genotypes were of identical
frequency, marker spacing, and pattern of missing data as the
actual genotypes, with individual phenotypes and pedigree
structure also preserved within each simulated dataset. For
markers in linkage disequilibrium (r
2$0.1), alleles were simulated
using the haplotype frequencies for the marker clusters. To reduce
computation time, those pedigrees of complexity greater than 70
bits were omitted from calculation of allele and haplotype
frequencies. Each simulated dataset was analyzed as described
above in two ways: retaining the minimum P-value per gene, as
well as the calculating the threshold-truncated product of P-values
(atrunc#0.01) per gene. For the set of single-SNP hypotheses
corresponding to a gene, the truncated product method considers
the product of only those P-values falling below a specified
threshold, evaluating the probability of observing as significant a
product by chance. Whereas Fisher’s Combined Test assesses the
overall evidence for departure from the null, the truncated product
approach can be used to assess whether suggestive or significant
findings are truly significant [64]. Previous reports support the use
of a truncated product approach in conjunction with the PDT
[65]. Empirical significance was calculated from the proportion of
simulated gene-wise test statistics more significant than the actual
results (robs+1/nperm+1). We used an adaptive permutation
procedure, by which empirical P-values were obtained for 100,
1,000, 10,000, and 100,000 simulations. Only those observed
associations for which there were not at least ten more significant
simulated results were carried forward to each successive stage of
permutation analysis.
Supporting Information
Table S1 Chromosome 20 genes assayed, with corre-
sponding boundary SNPs. For each gene assayed, the
corresponding number of SNPs, position of the first SNP
{ and
its dbSNP identifier, and the position of the last SNP
{ and dbSNP
identifier are given.
{Where applicable i.e. for loci with available tag
SNPs.
(PDF)
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